west
nile
viru
genu
flaviviru
transmit
bird
occasion
anim
ornithophil
mosquito
viru
also
infect
human
caus
asymptomat
infect
case
clinic
case
progress
sever
neuroinvas
diseas
viru
also
present
threat
sinc
infect
remain
unappar
howev
viru
contain
blood
organ
asymptomat
infect
donor
transmit
recipi
infecti
tissu
paper
review
present
avail
method
achiev
laboratori
diagnosi
west
nile
viru
infect
human
discuss
promin
advantag
disadvantag
light
result
obtain
four
differ
extern
qualiti
assess
studi
carri
european
network
import
viral
diseas
enivd
west
nile
viru
wnv
envelop
spheric
singlestrand
rna
flaviviru
transmit
bird
ornithophil
mosquito
mainli
belong
genu
culex
occasion
transmit
mammalian
host
geograph
area
wnv
circul
encompass
africa
israel
north
america
south
america
australia
scatter
area
southern
central
europ
includ
russia
czech
republ
hungari
greec
romania
itali
southern
franc
portug
turkey
spain
least
two
distinct
genet
lineag
identifi
among
wnv
isol
divers
area
lineag
includ
american
european
african
strain
wherea
lineag
contain
mainli
subsaharan
african
isol
although
lineag
strain
detect
human
mosquito
outsid
africa
addit
lineag
propos
lineag
includ
virus
isol
czech
republ
rabensburg
strain
caucasu
india
respect
sixth
lineag
recent
describ
indonesia
put
seventh
lineag
identifi
spain
strain
belong
lineag
nucleotid
diverg
wide
divers
togeth
elev
threat
human
health
pose
wnv
infect
result
develop
varieti
method
laboratori
diagnosi
import
emphasis
human
infect
caus
wnv
remain
asymptomat
therefor
approxim
case
becom
clinic
evid
clinic
syndrom
associ
wnv
human
infect
predominantli
mild
flulik
fever
wnv
fever
less
develop
sever
neuroinvas
diseas
detail
case
classif
wnv
infect
propos
concern
laboratori
diagnosi
viru
pleas
refer
conclus
paper
paper
review
current
avail
techniqu
identif
wnv
infect
human
four
extern
qualiti
assess
eqa
studi
perform
two
molecular
diagnost
wnv
infect
two
serolog
method
result
studi
present
end
review
focus
main
diagnost
problem
current
laboratori
method
diagnosi
infect
wnv
belong
two
main
categori
serolog
viral
detect
viru
isol
wnv
readili
isolat
tissu
plasma
serum
csf
sampl
cell
cultur
use
either
mammalian
mosquito
deriv
cell
line
vero
moreov
procedur
must
perform
biosafeti
level
condit
gener
take
day
appear
cpe
viru
isol
readili
accomplish
follow
procedur
collect
sampl
adher
whenev
possibl
sampl
collect
steril
condit
collect
media
contain
antibiot
immedi
refriger
optim
condit
sampl
inocul
onto
suscept
cell
cultur
within
minut
collect
possibl
time
interv
kept
minimum
alway
less
hour
gener
condit
met
refer
laboratori
dedic
research
facil
isol
wnv
strain
provid
ad
valu
allow
studi
research
pathogenesi
genet
variat
evolut
epidemiolog
etc
b
molecular
method
wnv
genom
peripher
blood
usual
detect
day
day
postinfect
time
usual
possibl
identifi
viral
rna
serum
andor
plasma
sampl
addit
detect
viruria
molecular
method
demonstr
use
tool
enabl
detect
wnv
genom
even
prolong
time
postinfect
routin
detect
wnv
rna
use
molecular
techniqu
two
distinct
diagnost
set
first
involv
blood
organ
donat
screen
subject
live
area
wnv
circul
known
occur
second
involv
identif
viral
genom
serum
plasma
csf
sampl
patient
present
clinic
pictur
typic
wnv
infect
blood
organ
safeti
screen
transmiss
wnv
human
blood
transfus
tissu
organ
transplant
record
usa
recent
europ
order
increas
biolog
safeti
blood
organ
donat
screen
polici
implement
area
human
case
wnv
relat
diseas
known
present
sinc
believ
least
wnv
infect
popul
remain
asymptomat
phase
viral
rna
actual
detect
blood
diagnost
set
basic
requir
laboratori
achiev
high
sensit
valu
sinc
techniqu
must
appli
healthi
total
asymptomat
popul
hypothet
wnv
load
could
low
genom
copiesml
two
commerci
nucleic
acid
amplif
test
nat
present
abl
detect
genom
low
level
first
base
polymeras
chain
reaction
pcr
technolog
manufactur
roch
diagnost
mannheim
germani
second
transcript
mediat
amplif
tma
test
avail
novarti
diagnost
emeryvil
ca
usa
assay
patent
target
sequenc
avail
user
fulli
autom
high
throughput
instrument
allow
test
hundr
plasma
sampl
per
day
elev
numer
perform
requir
blood
bank
workflow
analyt
sensit
test
state
manufactur
confid
interv
ci
ci
genom
equivalentsml
tma
pcr
evalu
lineag
wnv
strain
respect
sensit
valu
within
standard
wnv
blood
screen
product
set
us
food
drug
administr
within
copiesml
specif
method
consid
quit
high
howev
fals
posit
reaction
report
due
presenc
usutu
usuv
viru
close
relat
wnv
depend
local
epidemiolog
preval
wnv
infect
blood
screen
perform
individu
sampl
idnat
pool
sampl
usual
minipool
specimen
mpnat
idnat
test
sensit
two
altern
techniqu
use
manual
perform
real
time
rtpcr
qiagen
hilden
germani
nucleic
acid
sequenc
base
amplif
nasba
recent
report
popul
tissu
organ
donor
good
perform
term
turnaround
time
clinic
perform
patient
suspect
wnv
neuroinvas
diseas
wn
fever
viral
load
biolog
specimen
blood
csf
urin
patient
suspect
wnv
infect
hypothes
higher
asymptomat
infect
subject
consequ
diagnost
method
need
high
sensit
requir
screen
test
use
asymptomat
individu
revers
transcript
pcr
rtpcr
sensit
convent
rtpcr
wnv
detect
depend
mainli
target
sequenc
test
base
primer
target
c
gene
prm
gene
detect
viral
rna
equival
approxim
plaqu
form
unit
pfu
deriv
cell
grown
isol
nest
rtpcr
techniqu
increas
fold
rna
detect
threshold
method
prone
contamin
requir
longer
time
perform
increas
involv
laboratori
personnel
use
panspecif
rtpcr
techniqu
capabl
identifi
flavivirus
mainli
base
nest
assay
potenti
differenti
wnv
relat
diseas
infect
caus
flavivirus
amplicon
obtain
use
labour
intens
method
need
sequenc
obtain
electropherogram
analys
order
identifi
infect
viru
precis
indic
provid
present
method
use
differenti
divers
wnv
lineag
one
anoth
recent
publish
paper
field
wnv
phylogeni
base
analysi
ns
e
gene
realtim
rt
pcr
method
gener
rapid
reliabl
use
detect
wnv
larg
varieti
sampl
includ
nonhuman
specimen
anim
tissu
mosquito
differ
technic
modif
propos
last
year
gener
taqman
probebas
assay
quit
sensit
approxim
detect
limit
pfu
viral
rna
sometim
incap
detect
emerg
genom
variant
viru
sybr
green
base
test
sensit
taqman
test
less
specif
decreas
specif
could
disadvantag
sinc
fals
posit
result
gener
divers
virus
advantag
given
broader
spectrum
wnv
variant
identifi
anoth
potenti
disadvantag
realtim
rtpcr
repres
gener
short
amplicon
obtain
suitabl
sequenc
molecular
character
given
strain
variat
wnv
season
season
differ
geograph
locat
new
diagnost
molecular
approach
propos
multiplex
pcrligas
detect
reaction
assay
rtpcrldr
base
contemporari
amplif
three
differ
genom
region
one
code
sequenc
two
nonstructur
gene
minim
risk
fals
neg
result
due
wnv
genet
variant
anoth
method
base
genomewid
rtpcr
overcam
undetect
wnv
isol
genom
differ
mention
wnv
isol
phylogenet
group
differ
lineag
lineag
overlap
area
europ
order
distinguish
lineag
novel
realtim
quantit
rtpcr
test
develop
test
show
extrem
high
differenti
capac
differ
cell
deriv
wnv
isol
level
genom
copi
wnv
overlap
geograph
sever
arbovirus
includ
flavivirus
alphavirus
bunyavirus
number
recognis
emerg
virus
increas
tropic
subtrop
region
new
multiplex
rtpcr
assay
develop
facilit
simultan
identif
exampl
chikungunya
viru
denv
jev
wnv
patient
sampl
techniqu
improv
earli
detect
multipl
arbovirus
becom
practic
realiti
potenti
rapid
costeffect
differenti
diagnosi
epidemiolog
surveil
c
immunohistochemistri
detect
wnv
antigen
use
histochem
protocol
tissu
obtain
fatal
enceph
case
avail
diagnost
purpos
mani
year
today
laboratori
procedur
perform
rare
usual
order
improv
certainti
clinic
diagnosi
case
laboratori
data
minim
data
diagnost
perform
assay
mainli
obtain
anim
specif
method
depend
larg
specif
qualiti
antiserum
use
sensit
mani
case
low
often
depend
amount
wnv
present
tissu
qualiti
tissu
investig
noteworthi
underlin
diagnost
approach
describ
paragraph
could
hamper
daili
routin
use
laboratori
diagnosi
wnv
infect
lack
standard
protocol
uncertainti
specif
sensit
specif
antibodi
detect
still
remain
wide
use
approach
diagnosi
wnv
infect
human
order
understand
applic
serolog
wnv
diagnosi
use
rememb
mean
time
detect
viral
rna
igm
igg
seroconvers
approxim
day
respect
determin
studi
perform
amongst
wnv
viraem
blood
donor
usa
main
weak
limit
clinic
relev
serolog
method
broad
antigen
crossreact
exist
flavivirus
quit
specif
viral
envelop
e
protein
neutralis
antibodi
respons
often
combin
less
specif
test
base
detect
antibodi
membran
nonstructur
ns
protein
amino
acid
sequenc
conserv
amongst
flavivirus
base
consider
princip
serolog
method
subdivid
two
main
group
first
includ
enzymelink
immunosorb
assay
elisa
immunofluoresc
base
test
second
includ
plaqu
reduct
neutral
test
carri
use
highli
sensit
lesssensit
endpoint
prnt
prnt
respect
requir
constant
avail
standardisedvalid
infecti
virus
appropri
cell
cultur
hemagglutinationinhibit
test
hia
still
use
detect
panflaviviru
immun
respons
wherea
complement
fixat
test
cft
rare
use
today
laboratori
techniqu
includ
first
group
wide
use
due
rel
applic
routin
laboratori
abil
autom
part
workflow
less
specif
consequ
inabl
distinguish
wnvspecif
crossreact
antibodi
respons
thu
posit
result
identifi
use
method
must
confirm
specif
test
ie
constitut
second
group
serosurvey
involv
individu
appear
healthi
may
infect
subclin
goldstandard
detect
immun
respons
prnt
method
abl
detect
specif
low
titr
low
avid
immun
respons
prnt
assay
definit
less
sensit
prnt
assay
therefor
appropri
studi
involv
detect
immun
respons
individu
present
clinic
appar
infect
almost
certainli
develop
detect
viraemia
clinic
infect
import
emphasis
either
analys
test
follow
guidelin
world
health
organ
includ
control
standardis
virus
known
readili
neutralis
antigen
close
relat
distinct
speci
wnv
second
group
techniqu
particularli
prnt
assay
labour
intens
gener
limit
refer
dedic
research
laboratori
appropri
biosafeti
level
could
attain
prnt
flaviviru
antibodi
respons
direct
famili
crossreact
epitop
viru
specif
epitop
e
protein
one
promin
immunogen
polypeptid
elicit
neutral
antibodi
nab
test
gener
perform
follow
standard
protocol
detail
method
defin
dengu
could
adapt
wnv
describ
standardis
protocol
determin
prnt
titr
sera
patient
protocol
could
use
also
determin
prnt
titr
sera
obtain
subclin
infect
last
method
particularli
use
carri
serosurvey
healthi
individu
determin
whether
previous
experienc
infect
wnv
virus
given
broad
antigen
crossreact
differ
flavivirus
divers
neutral
activ
human
igg
subclass
prnt
prnt
requir
evalu
nab
panel
relat
virus
base
present
known
epidemiolog
flaviviru
human
infect
europ
follow
virus
grown
either
mammalian
cell
line
eg
vero
mosquitoderiv
cell
includ
differenti
diagnost
purpos
act
control
crossreact
reaction
two
strain
wnv
lineag
one
recent
isol
europ
human
infect
prefer
low
passag
number
cell
cultur
one
refer
strain
exampl
italia
franc
use
old
strain
eg
avoid
one
strain
wnv
lineag
sinc
presenc
lineag
recent
identifi
greek
ongo
epidem
usuv
believ
present
central
europ
recent
report
caus
human
infect
select
clinic
epidemiolog
circumst
test
sampl
obtain
patient
travel
divers
geograph
area
prior
test
flavivirus
includ
panel
follow
japanes
enceph
viru
jev
widespread
asian
countri
larg
human
migrat
stream
europ
present
occur
whose
genom
recent
put
identifi
vector
itali
tickborn
enceph
viru
tbev
widespread
central
eastern
european
countri
order
complet
panel
two
addit
virus
also
includ
one
serotyp
dengu
viru
denv
light
larg
number
import
case
within
european
union
territori
travel
return
tropic
endem
area
recent
report
autochthon
activ
denv
scatter
area
franc
croatia
final
yellow
fever
viru
yfv
includ
panel
ensur
absenc
yfvvaccin
deriv
nab
gener
rule
given
complic
pattern
antibodi
crossreact
among
famili
flavivirida
nab
titr
consist
higher
wnv
titr
detect
control
virus
panel
also
technic
variat
test
protocol
issu
must
consid
compar
prnt
result
obtain
differ
laboratori
exampl
variat
techniqu
use
detect
nab
could
includ
incub
time
usual
hour
method
cytopath
effect
cpe
detect
direct
microscopi
stain
vital
dye
detect
autom
colorimetr
detect
diamet
dishwel
use
support
cell
monolay
infect
virus
micro
neutralis
titr
assay
mnta
b
hia
cft
test
nowaday
rare
use
diagnosi
wnv
infect
human
hia
test
requir
treatment
serum
remov
nonspecif
inhibitor
also
requir
daili
avail
fresh
erythrocyt
maintain
high
perform
moreov
hia
broadli
crossreact
cft
labour
intens
analyt
stage
read
phase
test
specif
sensit
suffer
lack
standard
antigen
prepar
obtain
differ
sourc
test
report
point
b
technic
difficult
time
consum
rel
insensit
possibl
except
test
earli
infect
requir
sever
day
result
deliv
consequ
diagnost
laboratori
today
serolog
diagnost
test
perform
eia
technic
simpler
perform
addit
highli
specif
incorpor
monoclon
ab
mab
c
eia
method
subdivid
three
main
categori
igm
antibodycaptur
eia
maceia
indirect
igg
eia
epitop
block
eia
method
advantag
rapid
reproduc
compar
detect
nab
hia
cft
test
suitabl
routin
detect
immun
respons
result
acut
viral
infect
igm
respons
usual
detect
within
first
week
wnv
infect
sometim
presymptomat
stage
plasma
serum
cerebrospin
fluid
csf
gener
persist
day
plasmaserum
prolong
persist
csf
day
post
infect
year
plasmaserum
viraem
blood
donor
standard
commerci
avail
maceia
use
plate
coat
antibodi
antihuman
igm
wnv
antigen
obtain
brain
experiment
infect
mice
secondari
immunoglobulin
monoclon
antibodi
mab
direct
wnv
conjug
hors
radish
peroxidas
use
serum
dilut
screen
gener
test
calcul
sensit
specif
technic
modif
igm
detect
recent
propos
order
increas
sensit
specif
clinic
perform
test
particular
introduct
ratio
method
calcul
igm
eia
result
demonstr
elimin
nonspecif
reactiv
use
recombin
highli
specif
antigen
epitop
locat
domain
iii
e
protein
whole
recombin
e
protein
produc
insect
larva
viruslik
particl
vlp
prem
e
protein
protein
propos
promis
result
order
increas
standard
antigen
prepar
reduc
cost
assay
gener
accept
identif
igm
respons
sign
probabl
wnv
infect
need
confirm
laboratori
criteria
primarili
fourfold
increas
serum
antibodi
ab
titr
differ
sampl
collect
acut
convalesc
stage
diseas
presenc
virusspecif
igm
csf
gener
accept
direct
evid
infect
thu
prompt
identifi
case
confirm
one
accord
eu
case
definit
although
gener
result
maceia
correl
well
prnt
crossreact
igm
ab
result
infect
jev
serocomplex
virus
gener
lower
igg
antibodi
respons
fals
posit
result
report
routin
use
maceia
indirect
igg
eia
detect
wnv
igg
eia
standard
method
wide
use
determin
immun
statu
wnv
either
suspect
patient
healthi
asymptomat
popul
major
limit
test
firstli
restrict
clinic
specif
due
extens
crossreact
flavivirus
reason
recommend
detect
igg
perform
combin
maceia
case
suspect
infect
sinc
persist
igm
may
last
week
diseas
onset
case
posit
igg
detect
techniqu
need
evalu
confirm
either
prnt
test
increas
igg
respons
later
cours
infect
report
specif
sensit
valu
commonli
use
commerci
avail
igg
eia
techniqu
respect
order
estim
time
cours
infect
two
commerci
avail
eia
method
focu
diagnost
cypress
ca
usa
euroimmun
germani
evalu
avid
igg
immun
respons
wnv
symptomat
diseas
use
sera
obtain
within
first
day
onset
infect
igg
avid
lower
wherea
avid
index
higher
correl
infect
last
least
day
determin
igg
avid
like
provid
addit
use
data
clinic
differenti
recent
previous
acquir
wnv
infect
new
test
base
immun
complex
ic
elisa
method
recent
propos
detect
igg
show
elev
capabl
discrimin
antibodi
respons
direct
wnv
tbev
similar
test
could
develop
order
discrimin
wnv
usuv
jev
murray
valley
enceph
viru
saint
loui
enceph
viru
infect
technic
variant
eia
identif
igg
call
epitopeblock
eia
method
base
competit
test
sera
wnv
specif
mab
bind
wnv
antigen
origin
develop
diagnosi
preval
studi
anim
sinc
speciesindepend
techniqu
also
recent
evalu
diagnosi
human
infect
result
obtain
show
method
applic
popul
previous
expos
flavivirus
wnv
result
lack
correl
prnt
find
previou
vaccin
jev
anoth
possibl
confound
factor
interpret
result
use
assay
routin
diagnosi
wnv
infect
mainli
depend
number
sampl
need
evalu
qualiti
train
laboratori
personnel
interpret
test
result
test
use
develop
inhous
individu
laboratori
usingwnv
infect
cell
cultur
consequ
techniqu
suffer
lack
standard
result
compar
laboratori
would
greatli
benefit
extern
qualiti
assur
eqa
evalu
shown
later
commerci
avail
test
euroimmun
germani
shown
specif
compar
prnt
test
studi
perform
sera
collect
human
wnv
outbreak
south
africa
addit
new
protocol
test
develop
detect
igm
igg
antibodi
method
report
exhibit
higher
specif
mac
eia
reduc
nonspecif
reactiv
relat
vector
transmit
virus
cellular
antigen
defin
quantiti
uninfect
cell
mix
wnvinfect
cell
uninfect
cell
obvious
expect
remain
nonreact
test
sera
order
achiev
practic
recommend
possibl
routin
use
serolog
test
describ
pleas
refer
tabl
four
extern
qualiti
assur
eqa
studi
assess
qualiti
wnv
diagnost
worldwid
perform
support
european
network
diagnost
import
viral
diseas
enivd
first
studi
assess
qualiti
molecular
detect
method
wnv
infect
conduct
second
one
serolog
detect
method
assess
first
eqa
studi
second
eqa
particip
ask
analys
provid
eqa
sampl
use
procedur
routin
use
suspect
human
case
assay
detail
type
method
use
supplier
commerci
kit
protocol
refer
request
particip
could
choic
diagnost
procedur
employ
regard
first
eqa
molecular
detect
method
overal
diagnost
perform
wnv
disappoint
compar
earlier
eqa
studi
emerg
agent
ebola
lassa
pox
sever
acut
respiratori
syndrom
virus
result
show
lower
detect
rate
lineag
wnv
second
eqa
molecular
method
show
improv
profici
laboratori
compar
first
eqa
perform
howev
result
suggest
detect
wnv
lineag
still
problemat
therefor
proceed
detect
lineag
need
particularli
inhous
assay
first
eqa
serolog
detect
method
particip
laboratori
pass
minimum
requir
success
perform
result
mainli
explain
high
rate
crossreact
sera
posit
relat
ab
particularli
specif
yfv
also
low
sensit
igm
detect
result
risk
overlook
wnv
acut
infect
agreement
previou
eqa
studi
serolog
detect
dengu
viru
infect
signific
differ
use
commerci
inhous
assay
second
eqa
serolog
detect
method
conduct
involv
particip
compar
compar
previou
studi
result
still
show
low
specif
igg
detect
method
demonstr
high
level
crossreact
flavivirus
likewis
low
sensit
igm
detect
also
observ
indic
still
need
improv
wnv
serolog
diagnost
test
studi
demonstr
import
qualiti
control
measur
detect
wnv
infect
result
clearli
indic
need
laboratori
improv
test
particular
avoid
crossreact
sera
contain
antibodi
specif
heterolog
flavivirus
also
achiev
lower
detect
limit
rtpcr
test
wnv
lineag
organis
compar
test
wellcharacteris
sampl
laboratori
given
opportun
identifi
weak
improv
methodolog
confirm
subsequ
studi
diagnosi
wnv
infect
primarili
base
clinic
evid
laboratori
data
obtain
standard
control
procedur
see
laboratori
requir
minim
inform
onset
symptom
major
clinic
featur
demograph
inform
perform
adequ
assay
accord
clinic
phase
often
use
sever
assay
requir
confirm
detect
wnv
infect
addit
divers
continu
evolut
circul
strain
requir
regular
revis
molecular
assay
utmost
import
period
particip
diagnost
laboratori
eqa
studi
order
maintain
possibl
improv
perform
detect
wnv
infect
